BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itself
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Investeringsmöjlighet: Bli delägare i global ledare inom AI-baserad videoanalys på säkerhetsmarknaden (annons)

Pressmeddelande

BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itself

MFN Publicerad: 02 Jul 12:00
BBS-Bioactive Bone

BBS-Bioactive Bone Substitutes Plc | Company Release | July 02, 2024 at 13:00:00 EEST

BBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself

BBS-Bioactive Bone Substitutes Plc's Board of Directors has decided to issue 450,000 shares without consideration to the company itself, for potential loan conversions as well as for other possible purposes, in accordance with authorisation from the Annual Shareholders' Meeting on June 13, 2024.

After the directed share issue, the Company holds 452,147 treasury shares, representing approximately 2.2 percent of the total shares, after the new shares have been registered in the trade register.

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
[email protected]

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
[email protected]

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itself

Bifogade filer

BBS-Bioactive Bone Substitutes Plc has resolved on a share issue without consideration to the company itselfhttps://storage.mfn.se/de227f24-9305-426d-b20d-b12df3e939f4/bbs-bioactive-bone-substitutes-plc-has-resolved-on-a-share-issue-without-consideration-to-the-company-itself.pdf

Nyheter om BBS-Bioactive Bone

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

Jämförelse: Vilken är Sveriges bästa fondrobot?Guide: Så börjar du spara i fonder som nybörjareTopplistor: Fonderna med bäst avkastning just nu
STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien BBS-Bioactive Bone

Senaste nytt